|
市場調査レポート
結核治療市場動向
Tuberculosis: Trends, Challenges, and Opportunities in a Resurging Market
|
当商品の販売は、2011年12月21日を持ちまして終了しました。
Abstract
TB is epidemic in many developing countries, owing in part to co-infection
with HIV and the emergence and spread of multidrug-resistant strains of TB
(MDR-TB). The general consensus among infectious disease experts is that the
entire globe will remain at risk for TB epidemics until active TB transmission
is eradicated. But TB drug development faces significant challenges, and for
the past 30 years, the pipeline of novel therapeutics for treatment of TB has
been sparse. Now, however, given various factors--the fact that TB
transmission has been on the rise since the early 1980s, the emerging threat
of MDR-TB, and TB's role as an opportunistic infection in HIV
patients--government agencies, nongovernmental organizations (NGOs), and
pharmaceutical companies have a renewed interest in developing drugs for TB.
In 2000, several foundations, government agencies, and NGOs established the
Global Alliance for TB Drug Development (TB Alliance). In this report, we
review TB epidemiology, etiology and pathophysiology, resistance patterns, and
treatment approaches, and we highlight challenges and opportunities for the
pharmaceutical industry
Table of Contents
- Contents Overview of Tuberculosis
- Etiology of Tuberculosis
- Pathophysiology of Tuberculosis
- Clinical Outcomes
- Risk Factors Associated with TB
- Co-Infection with HIV
- Other Immunocompromising Diseases
- Multidrug-Resistant Tuberculosis
- Trends in Global Prevalence and Incidence of TB
- Overview
- Drivers of TB Transmission
- Social Structure
- Health Care Infrastructure
- Immigration
- Global Incidence and Prevalence of MDR-TB
- Prevalence of MDR-TB in Newly Diagnosed TB Cases
- Prevalence of MDR-TB in Previously Treated TB Cases
- Therapies and Therapeutic Programs
- Current Therapies
- Therapeutic Programs for Treatment of TB
- Emerging Therapies
- Opportunities in the TB Market
|
